Displaying items by tag: neuronext

UAB was part of a national, multisite study that showed a drug for multiple sclerosis was effective in slowing down brain atrophy, or shrinkage.
UAB is renewed for another five years in NeuroNEXT, a national clinical research program in brain disorders.